Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib Combined With VIC-1911 for Advanced Hepatocellular Carcinoma
NCT06519721Phase 2Active, not recruiting
- Sponsor
- Renji Hospital
- Start
- Aug 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of TAS-119 in hepatocellular carcinoma (HCC) (2 arms), sponsored by Renji Hospital. Primary endpoint: Objective Response Rate at 2 years. Started Aug 2024; status: active, not recruiting.
02
Drugs
TAS-119
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06519721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06519721.